No advantage to omapatrilat over enalapril in heart failure . . .


The investigational vasopeptidase inhibitor omapatrilat is as effective as enalapril in preventing major adverse cardiac outcomes in patients with moderate to severe heart failure, but failed to show superiority, said Milton Packer, MD.

Related Content
© 2023 MJH Life Sciences

All rights reserved.